Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

Inclusion Criteria: * Age\>20 years * Histopathology-proven prostate adenocarcinoma * Non-metastatic localized disease * Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study * Subjects are willing to sign the informed consent and agree to comply with the study procedures Exclusion Criteria: * Chronic use (\> 2 weeks) of \> 10 mg/day of prednisone or prednisolone within 2 months of the screening (topical or inhalational corticosteroids are permitted) * Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry * Other conditions the investigators think may affect subjects' compliance